Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Remittent fever

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Remittent fever. Displaying page 1 of 1.
    EudraCT Number: 2012-001333-14 Sponsor Protocol Number: CCOA566B2303 Start Date*: 2012-03-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in t...
    Medical condition: This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused by Plasmodium falciparum in children.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005852-33 Sponsor Protocol Number: CCOA566B2306 Start Date*: 2016-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infant...
    Medical condition: The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants < 5 kg of body weight (BW) with u...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004461-85 Sponsor Protocol Number: CCOA556B2401 Start Date*: 2016-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic tre...
    Medical condition: This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on the number of cl...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005735-40 Sponsor Protocol Number: BCG-EHMI Start Date*: 2016-03-29
    Sponsor Name:Radboud university medical center
    Full Title: Safety and protective efficacy of BCG vaccination against controlled human malaria infection
    Medical condition: Plasmodium faciparum malaria prevention
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036655 Prevention of malaria LLT
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    18.1 10021881 - Infections and infestations 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004163-21 Sponsor Protocol Number: A0661157 Start Date*: 2015-04-06
    Sponsor Name:Pfizer Inc
    Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa
    Medical condition: Malaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004952-80 Sponsor Protocol Number: A0661158 Start Date*: 2015-04-03
    Sponsor Name:Pfizer Inc
    Full Title: Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala...
    Medical condition: Intermittent Preventive Treatment In Pregnancy (IPTp)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000290-20 Sponsor Protocol Number: 204889 Start Date*: 2017-09-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or wi...
    Medical condition: Healthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003763-11 Sponsor Protocol Number: CACZ885D2208 Start Date*: 2016-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of canakinumab in pediatric IVIG-naïve or refractory patients with active Kawasaki disease
    Medical condition: Active Kawasaki disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:12:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA